Goal HbA1c for Non-Pregnant Adults with Diabetes
For most non-pregnant adults with diabetes, target an HbA1c of <7% (53 mmol/mol), which reduces microvascular complications and has long-term macrovascular benefits when achieved early in the disease course. 1
Standard Target: <7% for Most Patients
The most recent and authoritative guidance from the 2025 ADA Standards of Care establishes <7% as the appropriate goal for many non-pregnant adults without severe or frequent hypoglycemia affecting health or quality of life 1. This target is supported by decades of evidence showing clear reductions in:
- Microvascular complications (retinopathy, nephropathy, neuropathy) - Grade A evidence 2, 3
- Long-term macrovascular disease when achieved soon after diagnosis 2, 3
The 2022 AACE guidelines recommend an even more aggressive target of ≤6.5% if achievable safely 4, though this represents expert consensus rather than definitive trial evidence showing superiority over 7%.
More Stringent Target: <6.5% for Select Patients
Consider targeting <6.5% in patients who meet ALL of the following criteria 1, 5:
- Short duration of diabetes (recently diagnosed)
- Long life expectancy (>10-15 years)
- No significant cardiovascular disease
- Treated with lifestyle or metformin only (low hypoglycemia risk)
- Can achieve target without significant hypoglycemia or treatment burden
This more aggressive approach is based on subset analyses suggesting greater microvascular benefit and potential cardiovascular benefit when intensive control begins early 2, 3.
Less Stringent Target: <8% for High-Risk Patients
Target <8% (or 7-8% range) for patients with ANY of the following 1, 5:
- History of severe hypoglycemia or hypoglycemia unawareness
- Limited life expectancy (<10 years)
- Advanced microvascular complications (proliferative retinopathy, end-stage renal disease)
- Advanced macrovascular disease (prior MI, stroke, heart failure)
- Extensive comorbid conditions (multiple chronic diseases, frailty)
- Long-standing diabetes where <7% is difficult despite intensive efforts
- Older adults (≥80 years) or those at high risk of falls
- Cognitive impairment
Critical Caveat on Intensive Control
The ACCORD, ADVANCE, and VADT trials demonstrated that aggressive lowering of HbA1c to near-normal levels in patients with long-standing diabetes and established cardiovascular disease does not reduce cardiovascular events and may increase mortality 2, 3. This is particularly true when:
- Diabetes duration exceeds 10 years
- Atherosclerosis is already established
- Multiple medications are required to achieve target
- Hypoglycemia risk is elevated
Practical Implementation Algorithm
Step 1: Assess patient characteristics
- Diabetes duration
- Cardiovascular disease presence
- Hypoglycemia history
- Life expectancy
- Comorbidities
- Current treatment complexity
Step 2: Assign initial target
- <6.5%: New diagnosis, healthy, low-risk treatment
- <7%: Most patients (default target)
- 7-8%: Any high-risk feature present
Step 3: Monitor and adjust
- If HbA1c <6.5% on pharmacotherapy: Deintensify treatment to reduce hypoglycemia risk and treatment burden 5, 1
- If target difficult to achieve: Reassess whether less stringent goal appropriate rather than escalating to high-risk regimens
- Reassess targets with changes in health status, comorbidities, or life expectancy 1
Key Pitfalls to Avoid
Do not aggressively pursue near-normal HbA1c in patients with long-standing diabetes and cardiovascular disease - this increases mortality without cardiovascular benefit 2, 3
Do not maintain intensive therapy in patients achieving HbA1c <6.5% - deintensify to reduce hypoglycemia and polypharmacy burden 5, 1
Do not use a one-size-fits-all approach - the 7% target is a starting point, not an absolute mandate for all patients 1
Do not ignore hypoglycemia in pursuit of targets - severe hypoglycemia carries immediate mortality risk that outweighs long-term microvascular benefits 1
Do not set performance measures below 8% - this creates perverse incentives for inappropriate intensive treatment 5
The evidence consistently supports individualized targets within the 6.5-8% range, with 7% serving as the reasonable default for most patients when balanced against safety, treatment burden, and realistic benefit based on life expectancy and disease characteristics.